<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03994263</url>
  </required_header>
  <id_info>
    <org_study_id>MT-09</org_study_id>
    <nct_id>NCT03994263</nct_id>
  </id_info>
  <brief_title>A Prospective Study to Observe the Mechanism of Action of the MediTate iTind in Subjects With Symptomatic BPH With MRI</brief_title>
  <official_title>A Pilot and Prospective Study to Observe the Mechanism of Action of Medi-Tate i-Temporary Implantable Nitinol Device (iTind) in Subjects With Symptomatic Benign Prostatic Hyperplasia (BPH) With Magnetic Resonance Imaging (MRI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medi-Tate Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medi-Tate Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A total of up to 15 eligible subjects will be enrolled into this open-labeled one-arm study&#xD;
      designed to observe the mechanism of action of iTind when using MRI&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Objective:&#xD;
&#xD;
      To validate the iTind efficacy by using MRI in subjects with symptomatic BPH. Specifically&#xD;
      the pressure points created by the iTind's struts and its implications on blood flow to the&#xD;
      prostate will be assessed.&#xD;
&#xD;
      Efficacy Endpoints:&#xD;
&#xD;
      The endpoints of this study are:&#xD;
&#xD;
        -  Decrease in transition zone volume&#xD;
&#xD;
        -  Monitor size and location of ablative lesions&#xD;
&#xD;
        -  Monitor change in time of lesions&#xD;
&#xD;
        -  Monitor the correspondence change in prostate tissue All the above will be assessed by&#xD;
           using MRI.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    low recruitment&#xD;
  </why_stopped>
  <start_date type="Actual">November 18, 2019</start_date>
  <completion_date type="Actual">February 18, 2021</completion_date>
  <primary_completion_date type="Actual">February 18, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AE rate</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence (% of subjects) and frequency (no. of events) of device related adverse events.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Unexpected SAE</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence (% of subjects) and frequency (no. of events) of unexpected serious adverse events deemed as related to Meditate iTIND and/or to implantation/retrieval procedures.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Device complications</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence (% of subjects) and frequency (no. of events) of Meditate iTIND and/or to implantation/retrieval procedures complications</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>BPH</condition>
  <arm_group>
    <arm_group_label>iTind arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ITind device implant</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ITind device implant</intervention_name>
    <description>device implanted for 5-7 days</description>
    <arm_group_label>iTind arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject signed informed consent form (ICF)&#xD;
&#xD;
          -  Age 40 and above- Male with symptomatic BPH.&#xD;
&#xD;
          -  IPSS symptom severity score ≥ 13&#xD;
&#xD;
          -  Peak urinary flow of &lt; 12 ml/sec&#xD;
&#xD;
          -  Prostate volume between 25 ml to 80 ml (assessed by pre-operative ultrasound - TRUS)&#xD;
&#xD;
          -  Blood CBC and biochemistry up to two weeks before screening, demonstrating: Normal&#xD;
             values of the PT, PTT and INR tests (Anticoagulants washout may be done two weeks&#xD;
             prior of device implantation)&#xD;
&#xD;
          -  Subject able to comply with the study protocol&#xD;
&#xD;
          -  Normal urinalysis and negative urine culture&#xD;
&#xD;
          -  Subjects that are able to undergo MRI.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A post void residual (PVR) volume &gt; 250 ml measured by ultrasound or acute urinary&#xD;
             retention&#xD;
&#xD;
          -  Confirmed or suspected bladder cancer;&#xD;
&#xD;
          -  Recent (within 3 months) cystolithiasis or hematuria;&#xD;
&#xD;
          -  Urethral strictures, bladder neck contracture, urinary bladder stones or other&#xD;
             potentially confounding bladder pathology;&#xD;
&#xD;
          -  An active urinary tract infection.&#xD;
&#xD;
          -  Enrolled in another treatment trial for any disease within the past 30 days.&#xD;
&#xD;
          -  Previous colo- rectal surgery (other than hemorrhoidectomy) or history of rectal&#xD;
             disease if the therapy may potentially cause injury to sites of previous rectal&#xD;
             surgery, e.g., if a transrectal probe is used;&#xD;
&#xD;
          -  Previous pelvic irradiation, cryosurgery or radical pelvic surgery;&#xD;
&#xD;
          -  Previous prostate surgery, balloon dilatation, stent implantation, laser&#xD;
             prostatectomy, hyperthermia, or any other invasive treatment to the prostate&#xD;
&#xD;
          -  Median lobe obstruction of the prostate (larger than 1cm).&#xD;
&#xD;
          -  Cancer that is not considered cured, except basal cell or squamous cell carcinoma of&#xD;
             the skin (cured defined as no evidence of cancer within the past 5 years)&#xD;
&#xD;
          -  Patient with renal dysfunction&#xD;
&#xD;
          -  Any serious medical condition likely to impede successful completion of the study&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Male with symptomatic BPH</gender_description>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Bschleipfer, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weiden Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kliniken Nordoberpfalz AG Klinik für Urologie, Kinderurologie und interdisziplinäres Prostatakarzinomzentrum</name>
      <address>
        <city>Weiden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 18, 2019</study_first_submitted>
  <study_first_submitted_qc>June 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2019</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

